Literature DB >> 16153459

Significance of Fas receptor protein expression in epithelial ovarian cancer.

Jennifer Reed1, Ardeshir Hakam, Santo V Nicosia, Domenico Coppola.   

Abstract

Fas receptor (FasR) is a cell surface receptor that, when activated, triggers apoptosis. It has been postulated that this receptor may be involved in the clearance of benign ovarian epithelial inclusion cysts (IC). In this study, we test the hypothesis that the expression of FasR changes among IC, cystadenoma (AD), tumors of low malignant potential (LMP), and invasive cancer (cystadenocarcinoma, CA). Formalin-fixed paraffin-embedded sections from 53 oophorectomy specimens representing 26 IC, 17 AD, 17 LMP, and 24 CA were stained using the immunohistochemical avidin-biotin-peroxidase method. We used a mouse antihuman monoclonal antibody Apo-1/Fas (Dako), at 1:5 dilution, after antigen retrieval. The stain was semiquantitatively scored by 3 observers evaluating the intensity of the stain and percentage of positive tumor cells. Statistical analysis was performed using the Wilcoxon rank sum test. Strong (score 6+/7+) and diffuse (>75%) luminal FasR stain was identified in 22 (85%) of 26 IC and 16 (94%) of 17 AD, but only in 6 (35%) of 17 LMP and 1 (4%) of 24 CA. Conversely, weak (score 2+/3+) and focal (<25%) FasR staining was observed in 7 (29%) of 24 CA, but in none of the IC, AD, or LMP. These differences were statistically significant (P < .05). The decreased expression of FasR in malignant ovarian epithelial neoplasms as compared with benign ovarian epithelial lesions suggests that a decreased sensitivity to Fas-mediated apoptosis may be involved in ovarian epithelial carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16153459     DOI: 10.1016/j.humpath.2005.06.015

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Glycyrrhetinic Acid inhibits cell growth and induces apoptosis in ovarian cancer a2780 cells.

Authors:  Venus Haghshenas; Shohreh Fakhari; Sako Mirzaie; Mohammadreza Rahmani; Fariba Farhadifar; Sara Pirzadeh; Ali Jalili
Journal:  Adv Pharm Bull       Date:  2014-08-25

2.  Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases.

Authors:  Stylianos Kykalos; Spuridon Mathaiou; Anastasios J Karayiannakis; Dimitris Patsouras; Maria Lambropoulou; Constantinos Simopoulos
Journal:  J Gastrointest Cancer       Date:  2012-06

Review 3.  Molecular targeted therapy in ovarian cancer: what is on the horizon?

Authors:  Roshni Kalachand; Bryan T Hennessy; Maurie Markman
Journal:  Drugs       Date:  2011-05-28       Impact factor: 9.546

4.  Suppression of hypoxia-inducible factor 2alpha restores p53 activity via Hdm2 and reverses chemoresistance of renal carcinoma cells.

Authors:  Andrew M Roberts; Ian R Watson; Andrew J Evans; David A Foster; Meredith S Irwin; Michael Ohh
Journal:  Cancer Res       Date:  2009-11-17       Impact factor: 12.701

Review 5.  The biology of ovarian cancer: new opportunities for translation.

Authors:  Robert C Bast; Bryan Hennessy; Gordon B Mills
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

6.  TMEM14A aggravates the progression of human ovarian cancer cells by enhancing the activity of glycolysis.

Authors:  Qingmei Zhang; Xiaohong Wang; Xuan Zhang; Jingfen Zhan; Binbin Zhang; Jin Jia; Jie Chen
Journal:  Exp Ther Med       Date:  2022-08-05       Impact factor: 2.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.